Justin Fallon, PhD is the Scientific Founder and Director of Tivorsan Pharmaceuticals, discusses his company’s plan for entering Biglycan into clinical trials and his compnay’s work with Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) Advocacy Groups.

Biglycan is a small, naturally occurring extracellular matrix protein naturally found in muscle. It is a 37kD polypeptide chain and is a member of the Small Leucine-Rich Repeat Proteoglycan (SLRP) family of proteins. In immature muscle, Biglycan regulates the expression of a key ensemble of cell surface proteins including utrophin, alpha and gamma sarcoglycan, and the NODS complex of nNOS, dystrobrevin and syntrophin.